N/A
Completed N=110
Evaluation of the A1CNow+ Test Kit
Source: ClinicalTrials.gov NCT00798486 ↗Enrolled (actual)
110
Serious AEs
0.0%
Results posted
Mar 2010
Primary outcomePrimary: Number of A1C Results Either Equal To Or Within +/- 13.5% of the Laboratory Method (ACCURACY) — 94; 71 number of A1c results
Summary
The purpose of this study was to assure that consumers can successfully use the new version of A1CNow+ along with revised instructional materials.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of A1C Results Either Equal To Or Within +/- 13.5% of the Laboratory Method (ACCURACY) |
94; 71 | — |
| SECONDARY Average Within Subject Coefficient of Variation CV (PRECISION) |
4.57 | — |
| SECONDARY Percentage of Subjects Who Experienced First Time Failures (FTF) During Testing |
11; 40 | — |
| SECONDARY Number of Participants Who Provided These Ratings For Overall Testing Experience With A1C Test Kit |
65; 38; 7; 0 | — |
Eligibility Criteria
Inclusion Criteria
- Adults (age 18 and older) approximately 80% being ≤55 years old
- Persons with:
- known diabetes (type 1 or type 2) and pre-diabetes - approximately 85% of subject population per site
- no known diagnosis of diabetes - approximately 15% of subject population per site
- Individuals who are interested in performing a test using the kit at home
- Individuals willing to complete all study procedures (including venous draw and allowing site staff to perform finger punctures)
- Individuals who are able to speak, read, and understand English
- Individuals able to read out loud the first 5 lines of the A1C Test Kit instructional materials to demonstrate ability to read the print (may use glasses, if needed)
Exclusion Criteria
- Individuals taking prescription anticoagulants (such as Warfarin or heparin) or have clotting problems that may prolong bleeding. (Taking Plavix or aspirin daily is not excluded)
- Individuals with known Rheumatoid Arthritis or other condition causing significant impairment of manual dexterity
- Individuals with a known hemoglobin variant such as HbS or HbC
- Individuals with any known disorder of the blood or blood-forming organs (such as recovery from blood loss, hemolytic anemia, or iron deficiency anemia)
- Individuals who have received a blood transfusion within the 4 months prior to the study.
- Persons with known infection with a bloodborne pathogen (e.g. HIV, hepatitis)
- Individuals working for a competitive medical device company
- Individuals who have participated in previous studies on the A1CNow+ product
- Persons missing a digit or partial digits on the hand
- Individuals with the following impairments which, in the opinion of the investigator, would seriously compromise the integrity of the study:
- Significant visual impairment
- Significant hearing impairment
- Cognitive disorder
- Any other condition as per investigator's discretion
Data sourced from ClinicalTrials.gov (NCT00798486). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.